A PHASE 3, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACORAMIDIS IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID POLYNEUROPATHY (ATTRIBUTE-PN STUDY)
- Registry ID
- EIDOS AG10-334
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- EIDOS THERAPEUTICS, INC.
- Last update
- 2022-01-06
Conditions
- TRANSTHYRETIN MEDIATED AMYLOIDOSIS
Related clinical trials
- TRITON-PN: A PHASE 3, GLOBAL, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (HATTR-PN)
- A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NUCRESIRAN IN PATIENTS WITH TRANSTHYRETINMEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY)
- A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF
ACORAMIDIS FOR TRANSTHYRETIN AMYLOIDOSIS PREVENTION IN THE YOUNG (ACT-EARLY TRIAL)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID POLYNEUROPATHY
View on source registry